Cellcura ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cellcura ASA Enters Asia with First Sale to IVF Institution in China
Cellcura ASA announced that it steps into Asia with the first sale of its ART Lab solution to Peking University Third Hospital IVF Center, People's Republic of China. The CellCura ART Lab Solution will be immediately operational for routine treatment in the clinic, which is looking to expand its treatment capacity in the next few years, cutting down on ever increasing waiting lists in the region. This first Chinese contract has been developed in partnership with a distributor Guangzhou Haoxin Instrument Co Ltd and their subsidiary Hong Kong Long Sense Development Ltd. The financial details were not disclosed.
Latest Developments for Cellcura ASA
Latest Key Developments in Medical
- St. Jude Medical Inc announces CE Mark approval and first use of FlexAbility Ablation Catheter
- Teleflex Inc receives FDA clearance for ARROW-Clark VectorFlow Chronic Hemodialysis Catheter
- Sartorius Stedim Biotech SA sees FY 2014 revenue guidance to reach upper end of prior range
- Sartorius AG confirms FY 2014 revenue guidance
- Share this
- Digg this